Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minimal optimal dose of Sugammadex during ambulatory dentistry surgery
2017-005074-19Phase 4Completed
- Sponsor
- Erasmus Hospital
- Start
- Mar 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, single-arm trial of Sugammadex, sponsored by Erasmus Hospital. Primary endpoints: Time to appearance of 4 twitches in TOF and Time to TOF ratio ≥0.9. Started Mar 2019; status: completed.
02
Drugs
Sugammadex
Beyond the preview
Go deeper on 2017-005074-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005074-19.